Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 6/20 | 0.48 |
| ▸ | CCND1 | P24385 | 6/20 | 0.48 |
| ▸ | CCND2 | P30279 | 6/20 | 0.48 |
| ▸ | CCND3 | P30281 | 6/20 | 0.48 |
| ▸ | BRD4 | O60885 | 5/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 3/20 | 0.41 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | BTK | Q06187 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16285677 | 0.91 | JAK2 (0.49) | CDK4CCND1CCND2CCND3BRD4 | |
| SCHEMBL16285702 | 0.88 | BRD4 (0.45) | CDK4CCND1CCND2CCND3BRD4 | |
| SCHEMBL16286122 | 0.88 | FGFR4 (0.44) | CDK4CCND1CCND2CCND3FYN | |
| SCHEMBL16286127 | 0.88 | CDK4 (0.42) | CDK4CCND1CCND2CCND3BRD4 | |
| SCHEMBL16285672 | 0.86 | CCND3 (0.47) | CDK4CCND1CCND2CCND3FYN | |
| SCHEMBL16285699 | 0.85 | CDK4 (0.46) | CDK4CCND1CCND2CCND3FYN | |
| SCHEMBL16285713 | 0.85 | CDK4 (0.46) | CDK4CCND1CCND2CCND3FYN | |
| SCHEMBL16285692 | 0.85 | CDK4 (0.46) | CDK4CCND1CCND2CCND3FYN | |
| SCHEMBL16285685 | 0.83 | FYN (0.47) | CDK4CCND1CCND2CCND3FYN | |
| SCHEMBL16285681 | 0.83 | FYN (0.56) | CDK4CCND1CCND2CCND3BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | GRIN2A, GRIN2C, GRIN3A | CDK4 2824/4885CCND1 4822/4885CCND2 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.